Comorbidities as a prognostic factor in cardiological patients with COVID-19
DOI:
https://doi.org/10.52076/eacad-v4i3.515Keywords:
Heart disease; Comorbidities; COVID-19; Coronavirus.Abstract
Introduction: COVID-19 is a disease that has been ravaging the world's population since 2019. With a beginning imprecise in the city of Wuhan, China, the disease spread quickly and catastrophically, causing the infection of more than 400 million people. people and culminating in almost 6 million deaths (WHO, 2022). It is known that the pathology is caused by a coronavirus with systemic respiratory manifestations, however, it affects other systems, such as the cardiovascular system. Therefore, it is necessary to study the impacts that comorbidities bring with them on the prognosis of patients infected with SARS-CoV-2. Objective: The objective of this study was to analyze the correlation between comorbidities and the prognosis of cardiac patients with COVID-19 between March 2020 and September 2021, in a hospital in western Paraná. Methodology: A retrospective cross-sectional cohort study was carried out by surveying and analyzing medical records of patients who met the research inclusion criteria, with subsequent elaboration of statistics and graphs in order to elucidate the guiding question. Results and Discussion: A significantly higher rate of deaths was found among those who had at least one comorbidity; being related to the pathophysiology of the virus to the human body and the weaknesses caused by associated risk factors. Conclusion: This study points out the presence of at least one comorbidity as a worsening of the prognosis, being present in 70% of deaths.
References
ABOUGHDIR, M. et al. Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review. Viruses. 2020 May;12(5):527.
ANDREW, M. et al. COVID-19, ACE2, and the Cardiovascular Consequences. Am J Physiol Heart Circ. Invited Perspective “COVID-19, ACE2. April 2020. doi:10.1152 / ajpheart.00217.2020
COLLET, J. P. et al. ESC Scientific Document Group. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;29:ehaa575.
CORONAVIRUS RESOURCE CENTER. Johns Hopkins University of Medicine. Disponível em: https://coronavirus.jhu.edu/map.html. Acesso em: 27/02/2022.
GUO, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020.
HOFFMANN, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020, 181, 271–280.e8.
JESSUP, J. et al. Effect of angiotensin II blockade on a new congenic model of hypertension derived from the transgenic Ren-2 rat. Am J Physiol Heart Circ Physiol 291: H2166–H2172, 2006. doi: 10.1152/ajpheart.00061.2006.
KANG, Y. et al. Cardiovascular manifestations and treatment considerations in covid-19. Coração jnl. 2020– 317056. doi: 10.1136 / heartjnl-2020-317056.
KAR, S. et al. Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing-induced heart failure. J Appl Physiol (1985) 108: 923–932, 2010. doi:10.1152/japplphysiol.00840.2009. 20093667.
KEIDAR, S. et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 97: 946– 953, 2005. doi:10.1161/01.RES.0000187500.24964.7A. 16179584.
LI, J. et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020. doi: 10.1001/jamacardio.2020.1624.
MEHRA, M. et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. NEJM. 2020. doi: 10.1056/NEJMoa2007621.
MUELLER, C. et al. ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association. Cardiovascular biomarkers in patients with COVID-19. European Heart Journal: Acute Cardiovascular Care (2021) 10, 310–319.
ÖZYILMAZ, S. et al. Assessment of the Relationship between Mortality and Troponin I Levels in Hospitalized Patients with the Novel Coronavirus (COVID-19). Medicina (Kaunas): MDPI, 2020.
SEETHE, L. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611–2618. 2004.
SHI, S. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020. doi:10.1001/ jamacardio.2020.0950. 2020.
TANG, Y. et al. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front Immunol. 2020 Jul;11:1708.
WHO Coronavirus (COVID-19). Dashboard. WHO, 2022. Disponível em: https://covid19.who.int/. Acesso em: 27/02/2022.
YANG, G. et al. Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study. Hypertension. 2020. doi: 10.1161/HYPERTENSIONAHA.120.15143.
ZHANG, P. et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ. Res. 2020. doi: 10.1161/CIRCRESAHA.120.317134.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Gislaine Cadori; Bruna Bernegozzi Bessa; Rui M. S. Almeida
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
